BaFin probes Eckert & Ziegler’s 2024 accounts over Pentixapharm spin-off treatment

• BaFin opened a special review of Eckert & Ziegler’s 2024 consolidated financial statements tied to the October 2024 Pentixapharm spin-off.
• Regulator is assessing whether ongoing control relationships blocked off-balance-sheet derecognition of Pentixapharm assets and liabilities.
• A different accounting treatment could shift the items into earnings, lifting profit from discontinued operations in 2024.
• Company flagged no impact on operating key figures or subsequent years from the potential reclassification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eckert & Ziegler SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2369628_en) on July 22, 2026, and is solely responsible for the information contained therein.